Skip to main content
61°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89bio, Inc. - Common Stock
(NQ:
ETNB
)
6.270
-0.590 (-8.60%)
Streaming Delayed Price
Updated: 11:29 AM EDT, Apr 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
October 10, 2023
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
89bio, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for 89bio
September 22, 2023
Via
Benzinga
Analyst Ratings for 89bio
August 10, 2023
Via
Benzinga
BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
July 03, 2023
Via
Benzinga
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
89bio, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
July 03, 2023
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to...
Via
Benzinga
What 6 Analyst Ratings Have To Say About 89bio
July 03, 2023
Via
Benzinga
Analyst Ratings for 89bio
May 08, 2023
Via
Benzinga
3 Biotech Buyout Targets to Watch
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
April 19, 2023
Via
Investor Brand Network
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
June 13, 2023
Via
Benzinga
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
April 10, 2023
Via
Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
March 31, 2023
Via
Investor Brand Network
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
May 23, 2023
First FGF21 analog to enter Phase 3 development
From
89bio, Inc.
Via
GlobeNewswire
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
March 31, 2023
Although US stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning
March 24, 2023
Via
Investor Brand Network
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
May 02, 2023
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
